Eventide Healthcare & Life Sciences Fund

Class C (ETCHX)

EVENTIDE

Semi-Annual Shareholder Report - December 31, 2024

Fund Overview

This semi-annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2024 to December 31, 2024. You can find additional information about the Fund at https://www.eventidefunds.com. You can also request this information by contacting us at 1-877-771-3836.

What were the Fund's costs for the last six months?

(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment	
Class C	\$116	2.33%* * Annualized	
Fund Statistics			
Net Assets		\$1,289,860,257	
Number of Portfolio Holdings			
Portfolio Turnover		20%	

Top 10 Holdings* (% of net assets)			
Holding Name	% of Net Assets		
Verona Pharma plc - ADR	4.4%		
Scholar Rock Holding Corporation	4.0%		
Mirum Pharmaceuticals, Inc.	3.7%		
Insmed, Inc.	3.6%		
Guardant Health, Inc.	3.4%		
Blueprint Medicines Corporation	2.9%		
Collegium Pharmaceutical, Inc.	2.9%		
Celldex Therapeutics, Inc.	2.7%		
Aura Biosciences, Inc.	2.6%		
Sarepta Therapeutics, Inc.	2.6%		

* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

Asset Weighting (% of total investments)



Common Stocks 91.9%

 Private Investments 5.4% Contingent Value Rights 0.1%
Warrant 0.3%

- Convertible Bonds 0.0%
- Money Market Funds 2.3%

Where can I find additional information about the Fund?

Additional information is available on the Fund's website (https://www.eventidefunds.com), including its:



- Prospectus
- Financial information
- Holdings
- Proxy voting information

You may elect to receive shareholder reports through electronic delivery or in paper, free of charge. You can contact your financial intermediary to request electronic delivery of your reports or that you receive paper copies of your reports. Your election to receive reports, whether through electronic delivery or in paper, will apply to all funds held with your financial intermediary.